The Cancer Genome Atlas (TCGA) has provided a “complete genomic roadmap” of muscle-invasive bladder cancer, according to Seth P. Lerner, MD, co-chair of the Analysis Working Group of the TCGA program for muscle-invasive bladder cancer. Dr. Lerner talks to Urology Times about the clinical relevance of the TCGA’s findings, possible implications for upper tract disease, and what
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
The level II code A9616 will be effective starting on October 1, 2025.
The company said it plans to report interim efficacy data from the trial in September 2025.
“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.
Justin Dubin, MD, discussed how patients’ growing trust in digital tools could be leveraged to support lifestyle changes and improve health outcomes.
In healthy aging men without developing diabetes mellitus, modest increases in HbA1c were linked with declines in sperm motility and erectile function.
Wang and Bukavina outline several cases of ctDNA’s utility in the space.
Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.
